Background: Maintenance of inhaled corticosteroids (ICSs) is recommended in adults with asthma. However, adherence rates in patients with mild asthma and side effects of long-term ICS use can lead to withdrawal.
Objective: To analyze the real-world outcomes of ICS withdrawal by analyzing data from the Korean National Health Insurance database.
Methods: Based on claims data from the National Health Insurance of Korea between 2011 and 2014, we identified patients diagnosed with asthma without chronic obstructive pulmonary disease or long-term systemic steroid use who had an ICS medication possession rate of more than 50% in a year. We compared patients who received ICS consistently (maintenance group) with patients who had no ICS prescription for more than 6 months (withdrawal group). We evaluated exacerbation leading to prescription of systemic steroid and emergency department visit or hospitalization.
Results: Excluding patients with chronic obstructive pulmonary disease and long-term systemic steroid users, we identified 145,511 patients for the asthma cohort (mean age, 60.0 years; ever-smoker, 63.5%): 132,175 maintained ICS and 13,336 withdrew ICS for more than 6 months. Only 71 patients (0.5%) experienced exacerbation leading to an emergency department visit or hospitalization in the withdrawal group. ICS was restarted within 1 year for 33.6% of the withdrawal group, and 90% of these patients restarted ICS within 158 days.
Conclusions: This nationwide study of patients with asthma, characterized by a high proportion of elderly and smokers, showed that ICS withdrawal in about 10% of patients appeared to confer relatively minimal harm and exacerbation leading to hospitalization was not common. Further prospective studies are warranted to carefully explore the safety of ICS withdrawal in younger, nonsmoking, and well-controlled patients with asthma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaip.2020.09.056 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
4-amino-3-(phenylselanyl) benzenesulfonamide attenuates intermittent cold stress-induced fibromyalgia in mice: Targeting to the Nrf2-NFκB axis.
Biochem Pharmacol
November 2024
Research Laboratory in Biochemical Pharmacology - LaFarBio, CCQFA - Federal University of Pelotas, UFPel, P.O. Box 354 - 96010-900 Pelotas, RS, Brazil. Electronic address:
Article Synopsis
- * The study involved male and female mice, which were divided into various treatment groups, and it found that 4-APSB significantly reduced pain and depressive-like symptoms in the mice that experienced ICS.
- * Additionally, 4-APSB improved oxidative stress levels and normalized important biochemical markers in the mice's brain and spinal cord, suggesting its potential as a treatment for fibromyalgia in both genders.
Real World Study on the Reasons for eScalation or de-Escalation of Inhaled ThEraPies in COPD Patients: the STEPINCOPD Multicenter Observational Study.
COPD
December 2024
Respiratory Medicine Department, University Hospital of Ioannina, Ioannina, Greece.
Article Synopsis
- The STEPINCOPD study investigated the factors influencing the escalation or de-escalation of inhaled COPD therapies in clinical practice, especially after updated guidelines were released in 2019 and 2020.
- Conducted over 12 weeks with 1429 patients from various centers in Greece, the study focused on understanding why patients had changes in their inhaled medication based on GOLD's 2021 recommendations.
- Findings revealed that reasons for treatment changes included lack of response to previous treatment and COPD exacerbations, with a high adherence rate (over 80%) to the GOLD recommendations among physicians, influenced by factors such as their age and patients' CAT scores.
Triple Therapy De-Escalation and Withdrawal of Inhaled Corticosteroids to Dual Bronchodilator Therapy in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review and Meta-Analysis.
J Clin Med
October 2024
Internal Medicine and Stroke Care Ward, Department of Promoting Health, Maternal-Infant, Excellence and Internal and Specialized Medicine (ProMISE) "G. D'Alessandro", University of Palermo, 90133 Palermo, Italy.
The interpretation of evidence on the de-escalation of triple therapy with the withdrawal of inhaled corticosteroids (ICSs) to dual bronchodilator therapy with a long-acting muscarinic antagonist (LAMA) and a long-acting beta-agonist (LABA) in patients with chronic obstructive pulmonary disease (COPD) is conflicting. We evaluated the efficacy and safety of ICS discontinuation from LABA-LAMA-ICS triple therapy compared to its continuation. : We searched PubMed, Embase, Scopus, Web Of Science, clinicaltrial.
View Article and Find Full Text PDFFactors Related to Nonachievement of Intensive Blood Pressure-Lowering Target in Patients with Intracerebral Hemorrhage.
Neurocrit Care
September 2024
Neurology Department, Hospital Universitari Arnau Vilanova, Lleida, Spain.
Background: Spontaneous intracerebral hemorrhage (ICH) is one of the most disabling forms of stroke. Intensive lowering of blood pressure (BP) has been postulated as one of the therapies that can improve functional outcomes. However, this intensive reduction is not always achieved.
View Article and Find Full Text PDFUtility of exhaled nitric oxide to guide mild asthma treatment in atopic patients and its correlation with asthma control test score: a randomized controlled trial.
BMC Pulm Med
August 2024
Parc Sanitari Sant Joan de Dèu, Camí Vell de la colonia, 25, Sant Boi de Llobregat, Barcelona, 08830, Spain.
Background: Fractional exhaled nitric oxide (FeNO) is used for the diagnosis and monitoring of asthma, although its utility to guide treatment and its correlation with other tools is still under discussion. We study the possibility to withdraw inhaled corticosteroid treatment in atopic patients with mild asthma based on the FeNO level, as well as to study its correlation with other clinical control tools.
Methods: Prospective and randomized study including atopic patients aged 18 to 65 with mild asthma, stable, on low-dose inhaled corticosteroid (ICS) treatment, who had their treatment withdrawn based on a FeNO level of 40 ppb.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!